Humanized Preclinical Models: Transforming Early-Stage Drug Discovery with Aryastha Biosolutions®

Webinar: 11:30h – 13:00h

The Aryastha Biosolutions® Platform offers a comprehensive suite of advanced human-relevant preclinical models—including Patient-Derived Cells (PDCs), Tumor Organoids (PDTOs), Tumor Slice Cultures (PTSCs), and iTOX stem-cell–based toxicity models. These systems bridge the translational gap between in vitro research and clinical response, supporting Phase 0 trials to enhance predictability, reduce animal use, and improve clinical outcomes.

During the webinar, we’ll be showcasing our proprietary platform Aryastha Biosolutions®, which leverages humanized disease models to de-risk early-stage drug discovery and development. The platform aligns with the FDA Modernization Act 2.0, offering advanced screening and predictive technologies that enhance late-stage candidate qualification and improve clinical success rates. We will include case studies demonstrating how this platform has transformed decision-making for biotech companies during the early stages of discovery and development.

Registration link:
https://events.teams.microsoft.com/event/33eda2be-e9a1-4a89-97ae-9abeafffda70@8beb7e47-fef6-4a20-bdc6-c482cbfc79d5